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FoCuS: IMMuNoloGY AND IMMuNoTHERAPEuTICS
Vaccination: the Present and the Future 
Saheli Sadanand
Graduate School of Arts & Sciences, Department of Immunobiology, Yale School 
of Medicine, New Haven, Connecticut
Vaccines have undoubtedly saved the lives of millions, and along with improved sanitation,
they remain one of the cornerstones of modern medicine. Many diseases that were once
widespread are now eradicated, but vaccine programs face ongoing challenges. Safety con-
cerns as well as limited funding have led to pockets of reduced vaccine coverage around the
world ― including in developed countries. Chronic and recurrent diseases such as human
immunodeficiency virus (HIV†), tuberculosis, and malaria remain without effective vaccines.
This review will briefly describe vaccines and the two major issues faced by modern vacci-
nation programs: insufficient vaccine coverage and developing effective vaccines for chronic
and recurrent diseases. 
IntroductIon
Effective vaccines must induce protec-
tive immunity without pathogenesis. This
is achieved by attenuating or inactivating
viral or bacterial pathogens or by using
subunit  components  of  the  pathogen  or
pathogen toxins. The success of a given
vaccine depends on the stability of the anti-
gen as well as its ability to elicit immuno-
logical memory. In modifying the pathogen
or using a small part of it, some of the vac-
cine’s immunogenicity may be lost. There-
fore, some vaccines also contain adjuvants,
compounds  that  boost  the  inherent  im-
munogenicity of the altered pathogen. The
most commonly used adjuvant is alum, al-
though oil-in-water emulsions are now li-
censed for use in Europe and a lipid-based
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berculosis, malaria adjuvant is licensed for use in both Europe
and the United States [1]. Although alum has
been used in vaccines for years, the mecha-
nism(s) by which it improves vaccine im-
munogenicity  are  still  unclear  [2].  In
addition to an adjuvant, multi-dose vaccines
also contain a preservative to prevent con-
tamination.   
Vaccination leads to the generation of
long-lived plasma cells. These B cells can
survive clonally for the life of the individual
and  constantly  secrete  moderate-to-high
affinity  antibodies.  Antibodies  have  two
mechanisms  of  action. They  can  directly
neutralize the virus, bacteria, or bacterial
products, thereby preventing infection, and
they can mark infected cells for destruction
by other immune cells such as macrophages
and granulocytes. Vaccine-induced humoral
immunity can be assessed on an individual
basis  by  measuring  antibody  titers  to
pathogen-derived antigens at various times
post-immunization. Antibody half-life de-
pends on the nature of the vaccine antigen,
namely, whether it contains a repetitive epi-
tope and innate receptor ligands, and also on
the ability of the vaccine antigen to elicit
“help” from T cells (which assist B cells in
differentiating into plasma cells) [3]. The
diptheria,  tetanus,  and  pertussis  vaccine
(DTaP) contains single-epitope bacterial tox-
ins and induces the least stable antibody re-
sponses (antibody half-life of 10 to 20 years),
so protection must be maintained through
booster shots every decade [4]. Conversely,
the measles-mumps-rubella (MMR) vaccine
contains live attenuated versions of these
three viruses, and the mean antibody half-life
is greater than 100 years [4]. 
In addition to inducing the generation
of long-lived plasma cells, vaccination also
leads to the production of memory B cells
and memory CD8+ and CD4+ T cells. Un-
like long-lived plasma cells, which are ter-
minally differentiated B cells, memory B
cells have the capacity to undergo further
mutation and thereby enhance their affinity
and/or  to  differentiate  into  short-lived
plasma cells. The former property could be
particularly important for ensuring protec-
tion against evolving viruses, and indeed, it
does appear that memory B cells have un-
dergone affinity maturation in response to
repeated influenza vaccinations [5]. Gener-
ating memory T cells is not the primary out-
come of vaccination because T cells can
only respond to whole antigens once they
are processed and presented by antigen pre-
senting cells (nor do they undergo mutation
in response to antigen, as B cells do) and
CD8+ T cells require help from CD4+ T
cells (also known as helper T cells) to be-
come  memory.  However,  unlike  B  cells,
CD8+ T cells can directly kill infected cells.
Therapeutic vaccines are a new generation
of vaccines that would not protect against in-
fection but rather induce memory T cells to
clear existing viral infections or even can-
cerous tumors [6]. However, for infections,
therapeutic vaccines may only be fully ef-
fective when viral load is low [7], and this
could suggest that therapeutic vaccination
campaigns will need to be repeated (and will
also be more expensive) to ensure pathogen
clearance. 
Vaccine schedules are determined by
disease risk and necessity for booster shots.
Most vaccines are administered to infants
and young children (age 6 and younger),
who are the most vulnerable to infection
complications and death. The Centers for
Disease Control and Prevention (CDC) rec-
ommend that all children 6 and younger re-
ceive  vaccines  against  the  following
diseases: hepatitis A, hepatitis B, rotavirus,
diptheria, tetanus, pertussis, Haemophilus
influenzae type B, polio, influenza, measles,
mumps, rubella, varicella zoster, and pneu-
mococcal disease [8]. All of these vaccines
require at least one booster shot, and some
are  combined  into  single  shots.  Booster
shots are necessary both because of the at-
tenuated or inactivated nature of the antigen
and because primary immune responses in
infants and children may not generate suffi-
cient memory cells [9]. The only vaccine
that routinely changes is that for flu. The in-
fluenza virus can mutate and re-assort its
RNA segments very rapidly, necessitating
new vaccines on a yearly basis [10]. 
A common misconception is that vac-
cines can and should protect against infec-
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who is vaccinated will be protected if ex-
posed to the actual pathogen. However, if a
sufficient percentage of the population is
vaccinated, the majority will be protected
from  infection  upon  pathogen  exposure.
Therefore, even if one or a few individuals
do get infected, the pathogen will be unable
to spread. This concept, colloquially known
as herd immunity, forms the basis for the
success of vaccines. Herd immunity is con-
tingent on an optimal vaccine coverage rate
that depends on how quickly a given infec-
tion could spread [11]. When the percentage
of  immunized  people  drops  below  this
threshold, the chances of a disease outbreak
increase. Although herd immunity has been
criticized as valuing the fitness of a com-
munity over that of an individual, it is in fact
much safer for an unvaccinated individual
to live in a vaccinated community than vice-
versa [12,13]. 
obstacles to VaccIne coVerage:
concerns about motIVatIons
and saFety
In  developing  countries,  safety  con-
cerns often stem from distrust of Western
health professionals. Some fear that vac-
cines are actually being used for population
sterilization or even infection, fears that are
not without basis [14]. Even seemingly le-
gitimate vaccination programs have had ul-
terior  motives.  In  2011,  the  Central
Intelligence Agency (CIA) started a hepati-
tis B vaccine campaign near the Pakistani
compound in which Osama bin Laden was
suspected to be hiding, ostensibly to collect
genetic information from bin Laden family
members [15]. They abandoned the vacci-
nation program before the second round of
shots, leaving the local population incom-
pletely protected. Health officials have since
expressed concerns that this sham vaccina-
tion program may undermine future vacci-
nation efforts in Pakistan, which is one of
the few countries where polio is still pres-
ent, and put the lives of field workers at in-
creased risk [16]. It is important that health
officials be prepared to deal with ethical
concerns about vaccine safety and vaccine
programs in an honest manner by acknowl-
edging past mistakes. It is helpful to engage
the support and participation of local physi-
cians who are familiar with the culture and
language  of  the  community.  Vaccination
programs can thus be adjusted to address
local fears. For example, concerns about
needles spreading HIV led to a precipitous
decline in vaccination rates in Uganda dur-
ing the 1990s, and subsequently, the Ugan-
dan health ministry introduced auto-disable
syringes (which can deliver only a single
vaccine dose) into their vaccination pro-
grams, leading to a significant recovery in
vaccine coverage [17]. 
In developed countries, some feel that
vaccination programs benefit doctors and
pharmaceutical companies more than the
wider population. There have been lapses in
ensuring vaccine safety in the past: The oral
live polio vaccine, though it could actually
cause the disease, was used for years in the
United States despite the existence of a safer
(but more expensive) inactivated polio vac-
cine (the oral live polio vaccine was discon-
tinued in the late 1990s) [18]. In the United
States and Europe, unfounded worries about
a  potential  link  between  vaccines  and
autism, instigated by a paper in The Lancet
in 1998 and propagated by a zealous net-
work of autism advocates and celebrity at-
tention,  have  contributed  to  significant
distrust of vaccines. The study, since re-
tracted  by  The  Lancet,  claimed  that  the
MMR  vaccine  induced  gastrointestinal
problems in children on the autism spectrum
[19]. Though the results were never repro-
duced,  the  MMR  vaccination  rate  plum-
meted in England [20] and has yet to fully
recover to an optimal rate [21]. Unfortu-
nately,  until  concrete,  well-publicized
progress is made in understanding the ge-
netic and potentially environmental bases
for autism spectrum disorders, there will
likely continue to be claims about a causal
link between vaccination and autism. Health
officials can allay these fears through better
communication with the general public. On
an  individual  basis,  doctors  should  take
extra time to explain to parents why their
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vaccines work. On a broader level, health of-
ficials should partner with advertising com-
panies  to  develop  television  and  print
advertising campaigns that can illustrate the
importance  of  vaccines.  Health  officials
should also resist capitulating to anti-vac-
cine movements unnecessarily. Thimerasol,
a mercury derivative once used as a vaccine
preservative, has been removed from many
vaccine formulations because of unfounded
fears that it may cause autism [22]. Only by
exhibiting confidence in vaccines can health
officials expect the general public to follow
suit. Finally, there should be a more efficient
global system for reporting adverse effects
of vaccines to allow decisions about with-
drawing  vaccines  from  the  market  to  be
made more efficiently [18]. 
There will never be a completely risk-
free vaccine, but problems can be minimized
through more coordinated surveillance ef-
forts, ensuring the accountability of vacci-
nation programs administered by outside
groups, improved dialogue about the impor-
tance and mechanism of vaccines, and pro-
grams tailored to address the concerns of the
local population. 
FundIng VaccIne desIgn and
dIstrIbutIon
Vaccines are a form of preventive care
and are cost effective when used widely and
when covered by insurance. However, the
costs  of  manufacturing,  distributing,  and
preserving vaccines can be prohibitive in
impoverished countries, and this is a major
impediment to achieving complete vaccine
coverage. The Global Alliance for Vaccines
and Immunization (now called the GAVI al-
liance) was founded in 2000 to alleviate the
burden of vaccines on developing countries,
lowering  costs  both  through  agreements
made  with  vaccine  manufacturers  and
through  improving  vaccine  manufacturer
competition. The alliance is financially sup-
ported by a combination of government and
private donations, and the governing board
includes representation from governments,
global  organizations  (UNICEF  and  the
WHO), and private foundations. GAVI eval-
uates and funds country-based vaccination
programs (the vaccines are distributed by
UNICEF [23]). In spite of the weakened
global economy, GAVI exceeded its target
donation amount at its most recent pledging
conference in July 2011 [24]. GAVI has had
to contend with accusations of misuse of
funds; unfortunately, some of the countries
with the lowest vaccination coverage rates
are also those with the most corrupt govern-
ments. Nonetheless, GAVI has achieved a
great deal [25], suggesting that private part-
nerships not only with governments but also
with global health organizations are the best
way forward for improving vaccine cover-
age. 
Vaccine funding can be divided into
several areas: policy, cohort development
(important to ensure vaccine quality control
and effectiveness), basic research, preclini-
cal research, and clinical trials. Most fund-
ing is directed toward these last two areas
despite sizable gaps in our understanding of
diseases such as AIDS and malaria [26]. In-
creasingly, vaccine researchers are seeing
the value of basic research (funding for basic
research on HIV has increased over the past
few years [26]) and the importance of creat-
ing communication bridges between those at
the bench and those involved in clinical re-
search [26]. Vaccine researchers themselves
are starting to diversify as the complexity of
pathogens, the manufacturing of vaccines,
and the sheer volume of data goes beyond
the scope of traditional immunologists and
pathologists and necessitates the involve-
ment of systems biologists [27]. An inte-
grated research approach that includes basic
scientists and clinicians is the best method
for improving vaccine design. 
mIssIng VaccInes: the challenge
oF VaccInatIng agaInst chronIc
dIseases 
Vaccine development for chronic dis-
eases is an ongoing challenge. Combined,
HIV, malaria, and tuberculosis affect more
than 100 million people [28], and in some
areas of the world, they are co-endemic. Un-
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ready exist, these three are chronic, poten-
tially dormant in infected individuals for
weeks  or  even  months.  Without  visible
symptoms and in areas that lack a consistent
medical presence, infected individuals are
unlikely to receive a diagnosis, increasing
the urgency of developing effective vac-
cines. Additionally, a single or double-shot
vaccination regimen could be insufficient
for lifelong protection. Bacille Calmette-
Guérin, the current vaccine against tubercu-
losis, prevents infection in children but is far
less effective for adults [27]. Finally, while
T cells may be relatively more important
than antibodies for protection against these
diseases  [27],  the  immune  responses  to
malaria, HIV, and tuberculosis remain in-
completely understood. For example, while
the pathogenesis of malaria (caused by one
of five species of the protist Plasmodium) is
well delineated, the relative importance of B
cells and T cells remains unclear [29]. And it
was only very recently that the mode of in-
nate recognition of Plasmodium ― the very
first line of defense for the human host ―
was tentatively established [30]. In order to
design effective or better vaccines against
HIV, malaria, and tuberculosis, the immune
responses to these pathogens must be better
described. Research should focus on the fol-
lowing areas: the quality of immunological
memory generated in chronic infections, the
effect of co-infection on memory cells, and
the role of malnutrition and/or undernour-
ishment in shaping the quality of the im-
mune response.
Research on immunological memory in
chronic infection is still in its infancy, but
many studies have suggested that B cells
and  T  cells  in  chronic  infection  are  ex-
hausted; that is, they are functionally stunted
and will soon die off. Unless they are titered
to high enough numbers, functionally com-
petent memory CD8+ T cells fail to prolif-
erate and clear chronic infection and they
also require CD4+ T cell help (in contrast to
memory CD8+ T cells in acute infection)
[31]. HIV infects and kills CD4+ T cells, so
this could partially explain why memory
CD8+ T cells are ineffectual in controlling
HIV infection for progressors. Although B
cells and T cells are thought to be exhausted
in patients infected with malaria, it has been
shown that functional memory B cells and
long-lived antibodies are present in infected
individuals  [32].  Unfortunately,  the  im-
munological  response  to  malaria  is  very
poorly understood ― even the Plasmodium
epitopes and antigen-derived peptides rec-
ognized by B cells and T cells are not well
characterized [29]. Insecticide-treated mos-
quito nets are a very cost-effective means for
preventing infection [33], and it is likely that
this has limited both funding for and focus
on developing a malaria vaccine. 
Like HIV, tuberculosis mycobacteria
co-opt the immune system in order to sur-
vive. Mycobacterium tuberculosis can lie
dormant for years inside granulomas within
the lungs. Although the bacteria are unable
to spread, the immunopathology induced by
the  granulomas  can  be  recurrent.  Unlike
HIV, and to some extent malaria, the tuber-
culosis antigen repertoire is stable [27]. Cur-
rently,  several  tuberculosis  vaccines  that
contain antigen or antigen subunits are being
tested. This is promising as it may help acti-
vate a diverse enough population of T cells
(and perhaps B cells) to prevent re-activa-
tion of the mycobacteria. 
Co-infection is a serious concern with
HIV, tuberculosis, and malaria. Disturbingly,
it has been shown that HIV viral load in-
creases occur during febrile malaria; unsur-
prisingly, HIV-infected individuals are more
susceptible to malaria and tuberculosis in-
fections [34]. Research on memory CD8+ T
cells has suggested that there is an inverse
correlation between inflammation and mem-
ory cell generation [35]. Therefore, co-in-
fection  likely  adversely  affects  the
generation of effective protective immunity,
and individuals already infected may be un-
able to respond successfully to vaccination. 
The relationship between nutrition and
the immune system has yet to be sufficiently
fleshed out, but it is known that vitamin A
deficiency negatively affects immunity [36]
and it is likely that other nutrients play sim-
ilarly important roles. Chronic infections af-
fect  millions  of  under-  or  malnourished
357 Sadanand: Vaccination: the present and the futurechildren and adults. Ideally, food programs
and vaccination campaigns could be tied to-
gether in order to enhance the generation of
protective immunity in these populations,
but this may not always be feasible. 
conclusIons 
Vaccinations are an integral part of a
healthy society, but in an age where many
have not seen the horrible effects of diseases
that were once commonplace, they are in-
creasingly undervalued. Health care work-
ers can and should better communicate the
importance of vaccines to skeptical patients.
Additionally, doctors and researchers must
acknowledge that clinical trials and vacci-
nation programs have been undermined by
medical  ethics  violations  and  improper
safety standards in the past and strive to en-
sure that similar judgment errors do not take
place in the future. 
Chronic and recurrent diseases such as
HIV, malaria, and tuberculosis affect millions
of people, many of whom live in underde-
veloped countries. Continued investments in
research for vaccines against these diseases
are necessary, but immunologists should not
shy away from partnerships with researchers
in other areas, particularly systems biology,
that may help more rapidly delineate patterns
in immune responses. 
There is much left to understand about
vaccines and how to best design and distrib-
ute them. Through cooperation between not
only researchers and health officials but also
political groups, investors, and public rela-
tions officials, vaccines can be better de-
signed and distributed. 
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